PWM
CRNX

Palumbo Wealth Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Palumbo Wealth Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309K Buy
8,260
+87
+1% +$3.23K 0.06% 188
2026
Q1 		$297K Buy
8,173
+2,368
+41% +$106K 0.07% 172
2025
Q4 		$270K Buy
+5,805
New +$258K 0.07% 183

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Palumbo Wealth Management's CRNX Position: Q2 2026 in Review

Palumbo Wealth Management increased its Crinetics Pharmaceuticals (CRNX) stake by 1.1% in Q2 2026, buying an estimated $3.23K and bringing the position to 8,260 shares worth $309K. The position accounts for 0.06% of the portfolio, ranked #188.

Palumbo Wealth Management first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Palumbo Wealth Management held 8,260 shares of Crinetics Pharmaceuticals worth $309K as of Q2 2026.
  • Palumbo Wealth Management bought 87 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $3.23K.
  • Crinetics Pharmaceuticals made up 0.06% of Palumbo Wealth Management's portfolio in Q2 2026, its #188 holding.
  • Palumbo Wealth Management first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Palumbo Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.